One of the better-quality companies in the pharmaceutical sector, AbbVie ( ABBV 2.35%) had a phenomenal year in 2025.

AbbVie (ABBV) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the ...

AbbVie is focused on pipeline expansion and diversification to address the upcoming patent cliff, with significant financial growth despite challenges. A deal with the Trump administration aims to ...

AbbVie Inc. (ABBV) is a worldwide biopharmaceutical company based in North Chicago, Illinois. It conducts research, develops, ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary endpoint of overall survival. Specifically, the partners' Epkinly failed to ...

Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P.

If you are wondering whether AbbVie’s current share price lines up with its underlying value, you are not alone. This article ...

Biopharmaceutical company AbbVie has reached an agreement with the Trump administration to invest $100 billion in its U.S. operations ...

On January 12, 2026, AbbVie and RemeGen announced an exclusive licensing agreement granting AbbVie rights to develop, ...

Applications for the 2026 AbbVie Foundation Health Equity Accelerator open on January 27, 2026, and close on March 8, 2026. For more information and to apply, please visit the accelerator website.

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology pipeline.

These stocks sport dividend yields ranging from 2.9% to 5.5%.